Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Accelerated Bone Degradation in Thyroid Carcinoma Patients during Thyroxine Treatment, Measured by Determination of the Carboxyterminal Telopeptide Region of Type I Collagen in Serum

Accelerated Bone Degradation in Thyroid Carcinoma Patients during Thyroxine Treatment, Measured... Introduction Patients with thyroid carcinoma need postoperative thyroxine Substitution. The optimal degree of thyrotropin _ donated froin Orion Diagnostica, Turku, Finland. Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32,1994 / No. H line, pyridinoline and deoxypyridinoline cross-links. However, if urinary hydroxyproline is used äs an index, the subject must receive a special diet. New techniques have been developed for the measurement of specific indicators of bone metabolism in a single serum sample. Type I collagen accounts for 90 percent of the organic matrix of bone. Carboxyterminal propeptide of type I procollagen is an indicator of type I collagen synthesis in the body, and carboxyterminal telopeptide parts of type I collagen are a corresponding indicator of the degradation of type I collagen. These new serum markers have made it possible to measure bone metabolism easily (4, 5). The aims of the present study were to examine: 1) whether long-term thyroxine treatment for the suppression of thyrotropin secretion has effects on biochemical markers of bone metabolism in thyroid cancer patients; 2) the value of thyrotropin, free thyroxine, and free triiodothyronine in the prediction of the possible alterations in bone metabolism. Taimela et al.: Acceleratcd bone degradation in thyroid cancer http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Chemistry and Laboratory Medicine de Gruyter

Accelerated Bone Degradation in Thyroid Carcinoma Patients during Thyroxine Treatment, Measured by Determination of the Carboxyterminal Telopeptide Region of Type I Collagen in Serum

Download PDF
6 pages

Loading next page...
 
/lp/de-gruyter/accelerated-bone-degradation-in-thyroid-carcinoma-patients-during-0yGhhqNNEY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
Copyright © 2009 Walter de Gruyter
ISSN
1434-6621
eISSN
1437-4331
DOI
10.1515/cclm.1994.32.11.827
Publisher site
See Article on Publisher Site

Abstract

Introduction Patients with thyroid carcinoma need postoperative thyroxine Substitution. The optimal degree of thyrotropin _ donated froin Orion Diagnostica, Turku, Finland. Eur. J. Clin. Chem. Clin. Biochem. / Vol. 32,1994 / No. H line, pyridinoline and deoxypyridinoline cross-links. However, if urinary hydroxyproline is used äs an index, the subject must receive a special diet. New techniques have been developed for the measurement of specific indicators of bone metabolism in a single serum sample. Type I collagen accounts for 90 percent of the organic matrix of bone. Carboxyterminal propeptide of type I procollagen is an indicator of type I collagen synthesis in the body, and carboxyterminal telopeptide parts of type I collagen are a corresponding indicator of the degradation of type I collagen. These new serum markers have made it possible to measure bone metabolism easily (4, 5). The aims of the present study were to examine: 1) whether long-term thyroxine treatment for the suppression of thyrotropin secretion has effects on biochemical markers of bone metabolism in thyroid cancer patients; 2) the value of thyrotropin, free thyroxine, and free triiodothyronine in the prediction of the possible alterations in bone metabolism. Taimela et al.: Acceleratcd bone degradation in thyroid cancer

Journal

Clinical Chemistry and Laboratory Medicine – de Gruyter

Published: Jan 1, 1994

There are no references for this article.